name: Niacinamide 2.0 g in 100 mL TOPICAL LIQUID [BREXTEM S]


name: PHENOXYETHANOL 0.162 g in 20 mL / XANTHAN GUM 0.08 g in 20 mL / BENZOIC ACID 0.024 g in 20 mL / WATER 16.4578 mL in 20 mL / BUTYLENE GLYCOL 0.46 g in 20 mL / PROPANEDIOL 0.4 g in 20 mL / POLYSORBATE 20 0.2 g in 20 mL / EDETIC ACID 0.0002 g in 20 mL / PROTEOGLYCAN 4 0.002 g in 20 mL / FRAGRANCE 13576 0.03 g in 20 mL / GLYCERIN 2 g in 20 mL / DEHYDROACETIC ACID 0.014 g in 20 mL TOPICAL CONCENTRATE [Anubis Barcelona]


name: PROPYLPARABEN 0.0000001 g in 5 mL / ALLANTOIN 0.0125 g in 5 mL / PANTHENOL 0.0025 g in 5 mL / FD&C YELLOW NO. 5 0.00001 g in 5 mL / PROPYLENE GLYCOL 0.0069 g in 5 mL / ARCTIUM LAPPA ROOT 0.000035 g in 5 mL / METHYLPARABEN 0.00500065 g in 5 mL / TIOXOLONE 0.01 g in 5 mL / WATER 3.12515585 mL in 5 mL / ALCOHOL 1.756 mL in 5 mL / POLYOXYL 40 HYDROGENATED CASTOR OIL 0.02 g in 5 mL / YEAST, UNSPECIFIED 0.01725 g in 5 mL / ASCORBYL PALMITATE 0.00005 g in 5 mL / RIBOFLAVIN 0.000003 g in 5 mL / ETHYLPARABEN 0.00000015 g in 5 mL / TOCOPHEROL 0.000001 g in 5 mL / CITRAL 0.000097 g in 5 mL / LIMONENE, (+)- 0.002095 g in 5 mL / POWDERED CELLULOSE 0.0003 g in 5 mL / ISOPROPYL ALCOHOL 0.0006 g in 5 mL / HYDROXYETHYL CELLULOSE, UNSPECIFIED 0.017 g in 5 mL / LEVOMENOL 0.0045 g in 5 mL / FARNESOL 0.0005 g in 5 mL / FRAGRANCE 13576 0.01 g in 5 mL / PHENOXYETHANOL 0.000003 g in 5 mL / BUTYLPARABEN 0.00000025 g in 5 mL / NIACINAMIDE 0.0001 g in 5 mL TOPICAL CONCENTRATE [Anubis Barcelona]


name: Panthenol 0.19 g in 100 mL TOPICAL LIQUID [BREXTEM H]


name: Eucerin Advanced Repair Moisturizing Foam


name: Eucerin Sensitive Mineral Face Protection


name: Extended Infusion Set 6mm Cannula 23" Tubing


name: Extended Infusion Set 9mm Cannula 23" Tubing


name: Extended Infusion Set 9mm Cannula 32" Tubing


name: Nivea Deep Nourishing Serum and Almond Oil


name: Nivea Lip Care Dewy Plus Hyaluronic Acid


name: Nivea Men Sensitive Calm Face and Beard Balm


name: Nivea Skin Toning and Firming Body Gel Cream


name: Skin-EEZ 10-20mmHg Compression Sock L/XL


name: Skin-EEZ 10-20mmHg Compression Sock S/M Black


name: Skin-EEZ 10-20mmHg Compression Sock S/M Tan


name: Skin-EEZ 10-20mmHg Compression Sock S/M White


name: Skin-EEZ 10-20mmHg Compression Socks L/XL Tan


name: Skin-EEZ 20-30mmHg Compression Sock S/M Black


name: Skin-EEZ 20-30mmHg Compression Sock S/M White


name: Skin-EEZ 20-30mmHg Compression Socks L/XL


name: Skin-EEZ 20-30mmHg Compression Socks L/XL Tan


name: Skin-EEZ 20-30mmHg Compression Socks S/M Tan


name: Skin-EEZ 30-40mmHg Compression Sock L/XL


name: Skin-EEZ 30-40mmHg Compression Sock S/M Black


name: Skin-EEZ 30-40mmHg Compression Sock S/M White


name: Skin-EEZ 30-40mmHg Compression Socks L/XL Tan


name: Skin-EEZ 30-40mmHg Compression Socks S/M Tan


name: Skin-EEZ Anti-Embolism Knee High L/XL White


name: Skin-EEZ Anti-Embolism Knee High S/M White


name: Skin-EEZ Anti-Embolism Thigh High L White


name: Skin-EEZ Anti-Embolism Thigh High L/XL White


name: Skin-EEZ Anti-Embolism Thigh High M White


name: Skin-EEZ Anti-Embolism Thigh High S White


name: Skin-EEZ Anti-Embolism Thigh High XL White


name: Skin-EEZ Anti-Embolism Thigh Length S/M White


name: Skin-EEZ Anti-Embolism Thigh Length White L


name: Skin-EEZ Arthritis Compression Gloves Unisex


name: Skin-EEZ Compression Foot Ankle Sleeve L/XL


name: Skin-EEZ Compression Foot Ankle Sleeve S/M


name: Skin-EEZ Diabetic Healing Socks L/XL Black


name: Skin-EEZ Diabetic Healing Socks L/XL White


name: Skin-EEZ Diabetic Healing Socks S/M Black


name: Skin-EEZ Diabetic Healing Socks S/M White


name: Cleanser Topical application Soap [NIVEA MEN ACTIVE CLEAN BODY WASH]


name: Stick, Multi Ingredient Topical application Stick [NIVEA DEWY LIP CARE]


name: Foam, Multi Ingredient Topical application Foam [EUCERIN LEG & FOOT]


name: Cream, Multi Ingredient Topical application Cream [EUCERIN FACE SKIN BALANCE NIGHT CREAM]


name: Lotion, Multi Ingredient Topical application Lotion [EUCERIN AFTER SUN]


name: Cream, Multi Ingredient Topical application Cream [EUCERIN ADVANCED REPAIR HAND]


name: Cream, Multi Ingredient Topical application Cream [NIVEA INTENSE HEALING]


name: Cream, Multi Ingredient Topical application Cream [NIVEA SKIN TONING & FIRMING GEL-CREAM]


name: Ointment, Multi Ingredient Topical application Ointment [NIVEA MEN SENSITIVE CALM FACE & BEARD BALM]


name: Cream, Multi Ingredient Topical application Cream [EUCERIN FACE SKIN BALANCE DAY CREAM]


name: Avobenzone/Homosalate/Octisalate/Octocrylene 3%-10%-5%-10% Topical application Lotion [COPPERTONE OIL-FREE+SHINE CONTROL FACE]


name: Avobenzone/Homosalate/Octisalate/Octocrylene 3%-9%-4.5%-9% Topical application Lotion [COPPERTONE EVERY TONE SUNSCREEN]


name: Avobenzone/Homosalate/Octisalate/Octocrylene 3%-10%-5%-5% Topical application Lotion


name: Avobenzone/Homosalate/Octisalate/Octocrylene 3%-7%-5%-5% Topical application Lotion


name: Zinc Oxide 24% Topical application Lotion [EUCERIN SENSITIVE MINERAL FACE SUNSCREEN]


name: Zinc Oxide 24.08% Topical application Lotion [COPPERTONE KIDS ROLL-ON SUNSCREEN]


name: Cleanser Topical application Foam [EUCERIN HYDRATING FOAMING CLEANSER]


name: Aluminum Chlorohydrate 18% Topical application Solution


name: Aluminum Zirconium Tetrachlorohydrex Gly 19% Topical application Stick


name: CARBOMER HOMOPOLYMER, UNSPECIFIED TYPE 0.025 g in 50 mL / GLYCERIN 0.005 g in 50 mL / LINOLENIC ACID 0.00275 g in 50 mL / TROMETHAMINE 0.22 g in 50 mL / OCTOCRYLENE 1.8 g in 50 mL / BUTYLATED HYDROXYTOLUENE 0.0018 g in 50 mL / PROPYLENE GLYCOL 2.5 g in 50 mL / WATER 27.55 mL in 50 mL / FRAGRANCE 13576 0.3 g in 50 mL / CARBOMER COPOLYMER TYPE A (ALLYL PENTAERYTHRITOL CROSSLINKED) 0.075 g in 50 mL / .ALPHA.-TOCOPHEROL 0.006 g in 50 mL / POLY(METHYL METHACRYLATE; 450000 MW) 2.1 g in 50 mL / AVOBENZONE 1.8 g in 50 mL / TITANIUM DIOXIDE 0.425 g in 50 mL / PHENOXYETHANOL 0.35 g in 50 mL / POLYETHYLENE GLYCOL 400 0.14225 g in 50 mL / LINOLEIC ACID 0.49725 g in 50 mL / SILICON DIOXIDE 0.575 g in 50 mL / ANHYDROUS CITRIC ACID 0.00025 g in 50 mL / ASCORBYL PALMITATE 0.00125 g in 50 mL / ASCORBIC ACID 0.00025 g in 50 mL / OCTISALATE 1.8 g in 50 mL / BEMOTRIZINOL 1.45 g in 50 mL / DIMETHICONE 1.25 g in 50 mL / OCTINOXATE 3.5982 g in 50 mL / BUTYLENE GLYCOL 2.5 g in 50 mL / C20-22 ALCOHOLS 0.3375 g in 50 mL / CHLORPHENESIN 0.1 g in 50 mL TOPICAL CREAM [AnubisMed]


name: ALLANTOIN 0.05 g in 50 mL / ALOE VERA LEAF 2.5 g in 50 mL / FRAGRANCE 13576 0.225 g in 50 mL / GLYCERYL MONOSTEARATE 0.875 g in 50 mL / TROLAMINE 0.3 g in 50 mL / BUTYLATED HYDROXYTOLUENE 0.0535 g in 50 mL / PROPYLENE GLYCOL 1.996 g in 50 mL / CETYL ALCOHOL 0.0038 g in 50 mL / TROPOLONE 0.004 g in 50 mL / TOCOPHEROL 0.0004 g in 50 mL / DIMETHICONE 0.25 g in 50 mL / 1,2-HEXANEDIOL 0.198 g in 50 mL / IMIDUREA 0.15 g in 50 mL / CARBOMER HOMOPOLYMER, UNSPECIFIED TYPE 0.25 g in 50 mL / CETEARYL ETHYLHEXANOATE 1.75 g in 50 mL / MEDIUM-CHAIN TRIGLYCERIDES 1.5 g in 50 mL / CAPRYLYL GLYCOL 0.198 g in 50 mL / OCTINOXATE 3.4965 g in 50 mL / GLYCERIN 0.4975 g in 50 mL / GLYCERYL STEARATE SE 1.5 g in 50 mL / WATER 27.4065 mL in 50 mL / C12-20 ACID PEG-8 ESTER 2.25 g in 50 mL / OXYBENZONE 2 g in 50 mL / DECYL OLEATE 1.9996 g in 50 mL TOPICAL CREAM [ANUBISMED]


name: GLYCERIN 0.15 g in 15 mL / WATER 11.358 mL in 15 mL / IMIDUREA 0.045 g in 15 mL / FRAGRANCE 13576 0.0375 g in 15 mL / TROPOLONE 0.0012 g in 15 mL / SILICON DIOXIDE 0.0024 g in 15 mL / CARBOMER HOMOPOLYMER, UNSPECIFIED TYPE 0.12 g in 15 mL / TROLAMINE 0.12 g in 15 mL / BUTYLATED HYDROXYTOLUENE 0.015 g in 15 mL / HEXAMETHYLENE DIISOCYANATE/TRIMETHYLOL HEXYLLACTONE CROSSPOLYMER 0.1176 g in 15 mL / ARGAN OIL 0.075 g in 15 mL / DECYL OLEATE 0.2999994 g in 15 mL / ALLANTOIN 0.015 g in 15 mL / C12-20 ACID PEG-8 ESTER 0.15 g in 15 mL / ALOE VERA LEAF 0.6 g in 15 mL / PROPYLENE GLYCOL 0.6 g in 15 mL / BUTYROSPERMUM PARKII (SHEA) BUTTER UNSAPONIFIABLES 0.15 g in 15 mL / CAPRYLYL GLYCOL 0.0588 g in 15 mL / MEDIUM-CHAIN TRIGLYCERIDES 0.375 g in 15 mL / TOCOPHEROL 0.0000006 g in 15 mL / 1,2-HEXANEDIOL 0.06 g in 15 mL / GRAPE SEED OIL 0.15 g in 15 mL TOPICAL CREAM [AnubisMed]


name: GLYCOLIC ACID 17 g in 50 mL / KOJIC ACID 2.5 g in 50 mL / HEXYLRESORCINOL 1 g in 50 mL / ASCORBYL GLUCOSIDE 0.25 g in 50 mL / LACTIC ACID 5 g in 50 mL / PHENOXYETHANOL 0.225 g in 50 mL / PROPYLENE GLYCOL 0.5 g in 50 mL / HYDROXYETHYL CELLULOSE, UNSPECIFIED 0.34875 g in 50 mL / ALCOHOL 6.3 mL in 50 mL / AMMONIA 2.75 g in 50 mL / ISOPROPYL ALCOHOL 0.75 g in 50 mL / WATER 7.333 mL in 50 mL / ETHYLHEXYLGLYCERIN 0.025 g in 50 mL / SALICYLIC ACID 1 g in 50 mL TOPICAL LIQUID [AnubisMed]


name: IMIDUREA 0.25 g in 50 mL / ALOE VERA LEAF 0.15 g in 50 mL / WATER 45.8293 mL in 50 mL TOPICAL LIQUID [AnubisMed]


name: ZINC OXIDE 0.0135 g in 1 g TOPICAL CREAM [Sheer Protection SPF 30]


name: Easy Comfort 0.3ML 31G 5/16 inch Insulin Syringe


name: Easy Comfort 0.3mL 31G 1/2 inch Insulin Syringe


name: CVS TENS Muscle Pain Therapy Replacement Pad


name: OneTouch Delica Safety 30G Single Use Lancing Device


name: OneTouch Ultra2 Blood Glucose Monitoring System


name: OneTouch Verio Flex Blood Glucose Monitoring System


name: TRACH CANNULA,INNER 7MM SMITHS #101858080


name: BANDAGE KIT,COMPRESSION COFLEX TLC CALAMINE LITE


name: TUBE FEEDING SET,EXTENSION ENFIT AMT #8-1255-ISOSAF


name: DRESSING,COLACTIVE PLUS AG PKT,POWDER,TOP


name: BANDAGE TUBULAR ELASTIC TUBIFAST LARGE LIMB


name: VAD DRIVELINE MAINTENANCE KIT CENTURION #DT16130


name: DRESSING,ZETUVIT PLUS 4IN X 4IN #4131100


name: TRACH STOMA PROTECTOR,BUCHANAN LITE LUMINAUD #38232


name: BANDAGE,STRETCH,URGOK2 7 1/8IN X 9 3/4IN


name: OCTINOXATE 7 g in 100 mL / ZINC OXIDE 6 g in 100 mL TOPICAL LOTION [Love your Sunscreen Broad Spectrum SPF 25]


name: OCTINOXATE 7 g in 100 mL / ZINC OXIDE 6 g in 100 mL TOPICAL LOTION [Stay Ageless Daily Moisturizer Sunscreen]


name: TITANIUM DIOXIDE 7.75 g in 100 mL / ZINC OXIDE 10 g in 100 mL TOPICAL CREAM [Stay AgelessTinted Mineral Sunscreen Broad Spectrum SPF 30]


name: ZINC OXIDE 7.725 mg in 50 mg TOPICAL CREAM [HYPOALLERGENIC CBD SENSITIVE SKIN THERAPY Ultra-Lightweight Calming Veil SPF 35]


name: silver/calcium alginate 12" TOPICAL BANDAGE


name: silver/silicone/foam bandage 2" X 2" TOPICAL BANDAGE


name: silver/silicone/foam bandage 6" X 6" TOPICAL BANDAGE


name: syringe,safety with needle,0.5 mL 30 gauge X 1/2" MISCELL SYRINGE, EMPTY DISPOSABLE


name: calcium alginate 4 1/4" X 4 1/4" TOPICAL BANDAGE


name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA


name: non-adherent bandage/sunflower oil/petrolatum,white 3" X 3" TOPICAL BANDAGE


name: non-adherent bandage/sunflower oil/petrolatum,white 3" X 8" TOPICAL BANDAGE


name: non-adherent bandage/sunflower oil/petrolatum,white 5" X 9" TOPICAL BANDAGE


name: OCTOCRYLENE 42 mg in 1 mL / AVOBENZONE 25.2 mg in 1 mL / HOMOSALATE 84 mg in 1 mL / OCTISALATE 42 mg in 1 mL TOPICAL SPRAY [Carnival Adventures Sport Sunscreen Broad Spectrum SPF 50]


name: ALUMINUM SESQUICHLOROHYDRATE 250 mg in 1 mL TOPICAL STICK [Power Stick Invisible Protection Roll- On Antiperspirant Deodorant Spring Fresh]


name: ZINC OXIDE 132 mg in 1 mL TOPICAL LOTION [Agent Natuer holi (sun) dewy tinted skin drops]


name: ZINC OXIDE 2.3175 g in 15 g TOPICAL CREAM [HYPOALLERGENIC CBD SENSITIVE SKIN THERAPY Ultra-Lightweight Calming Veil SPF 35]


name: OCTISALATE 50 mg in 1 mL / ZINC OXIDE 40 mg in 1 mL TOPICAL CREAM [Brickell Mens Products Daily Defense Face Moisturizer SPF-20]


name: OCTOCRYLENE 9 mg in 1 mL / OCTISALATE 5 mg in 1 mL / AVOBENZONE 3 mg in 1 mL TOPICAL LOTION [Sun-Light Sunscreen Broad Spectrum SPF 45]


name: Titanium Dioxide 2 g in 100 g / Zinc Oxide 17 g in 100 g TOPICAL CREAM [MD Mineral BB Creme Broad Spectrum SPF 50 Water Resistant (80min) Mineral Sunscreen DEEP]


name: Titanium Dioxide 20 mg in 1 mL / Zinc Oxide 170 mg in 1 mL TOPICAL CREAM [Mineral Creme SPF 50 Mineral Creme SPF 50 Broad Spectrum UVA-UVB Sunscreen Water Resistant (80 min)]


name: Titanium Dioxide 2 g in 100 g / Zinc Oxide 17 g in 100 g TOPICAL CREAM [MD Mineral BB Creme Broad Spectrum SPF 50 Water Resistant (80min) Mineral Sunscreen DARK]


name: OXYBENZONE 6 g in 100 mL / OCTISALATE 5 g in 100 mL / HOMOSALATE 10 g in 100 mL / OCTOCRYLENE 2.7 g in 100 mL / AVOBENZONE 3 g in 100 mL TOPICAL LOTION [Bee Bald Smooth Plus Daily Moisturizer SPF 30 Sunscreen]


name: TITANIUM DIOXIDE 81 mg in 1 g / ZINC OXIDE 60 mg in 1 g TOPICAL STICK [Solar SPF 40 Broad Spectrum SPF 40 Water Resistant (80 min) Mineral Suncreen]


name: PANTHENOL 0.501 g in 100 mL TOPICAL LIQUID [ReOrganic Eyelash Growth Boosting Serum]


name: ZINC OXIDE 6.6375 g in 6.6375 g TOPICAL LOTION [365. Everyday Value]


name: Calcipotriene;Dimethicone 0.005%; 5% Topical application Cream [CALSODORE KIT]


name: ZINC OXIDE 200 mg in 1 g TOPICAL LOTION [Baby Mineral Sunscreen Probiotics SPF55]


name: ZINC OXIDE 13.5 g in 100 g TOPICAL CREAM [Hale and Hush Broad Spectrum SPF 30 SPF 30]


name: Ethinyl Estradiol/Levonorgestrel;Ferrous Fumarate 0.02 MG-0.1 MG; 75 MG Oral Tablet


name: ZINC OXIDE 160 mg in 1 g / TITANIUM DIOXIDE 34 mg in 1 g TOPICAL SPRAY [Kids Mineral Sunscreen SPF50]


name: ZINC OXIDE 16.5 g in 100 mL TOPICAL LOTION [DAILY SUPERGOOP DOSE BIORETINOL MINERAL SPF 40]


name: LANOLIN 30 g in 100 g TOPICAL OINTMENT [HEN HEALER MULTI-PURPOSE]


name: NICOTINAMIDE MONONUCLEOTIDE 600 mg ORAL CAPSULE


name: Dimethicone;Mometasone Furoate 5%; 0.1% Multiple Routes Kit [MOMETACURE]


name: Avobenzone 30 mg in 1 g / Homosalate 100 mg in 1 g / Octisalate 50 mg in 1 g TOPICAL LIPSTICK [SUNPROOF NOURISHING LIP BALM Broad Spectrum SPF 24 Sunscreen FRESH MINT]


name: TITANIUM DIOXIDE 3.3 g in 100 mL / ZINC OXIDE 14.9 g in 100 mL TOPICAL LIQUID [NAKED SUNDAYS CABANA GLOW MINERAL GLOW SERUM DROPS BRONZE 40mL with wild Rosella SPF 50]


name: Zinc Oxide 160 mg in 1 g TOPICAL CREAM [Skin Apeel Ageless Defense SPF 40 Broad Spectrum]


name: Avobenzone 30 mg in 1 mL / Octisalate 50 mg in 1 mL / Octocrylene 27.5 mg in 1 mL TOPICAL LOTION [Gleam plus Glow SPF 50. SPF 50 Broad Spectrum Sunscreen UVA-UVB Sheer Glow Tint]


name: Avobenzone 30 mg in 1 mL / Octocrylene 27.5 mg in 1 mL / Octisalate 50 mg in 1 mL TOPICAL LOTION [Daily Antioxidant Moisturizer SPF 30. SPF 30 Broad Spectrum Sunscreen UVA-UVB]


name: ZINC OXIDE 250 mg in 1 g TOPICAL LOTION [earth mama UBER-SENSITIVE MINERAL Sunscreen SPF 40]


name: Avobenzone 30 mg in 1 mL / Octisalate 50 mg in 1 mL / Octocrylene 27.5 mg in 1 mL TOPICAL LOTION [Tint plus Tone SPF 50. SPF 50 Broad Spectrum Sunscreen Sheer Tinted Moisturizer]


name: Avobenzone 30 mg in 1 g / Octisalate 50 mg in 1 g / Homosalate 100 mg in 1 g TOPICAL LIPSTICK [Hydrating Sheer Lip Balm SPF 30 - BARE Broad Spectrum SPF 30 UVA-UVB Sunscreen]


name: HOMOSALATE 15 g in 100 g / OCTISALATE 5 g in 100 g / AVOBENZONE 3 g in 100 g / OCTOCRYLENE 10 g in 100 g TOPICAL SPRAY [SPF 50 Sunscreen Unfragranced]


name: NIACINAMIDE 5 g in 100 mL / ADENOSINE 0.04 g in 100 mL / ARBUTIN 5 g in 100 mL TOPICAL LIQUID [Reoganic EX Whitening Pore Care Deodorant]


name: TITANIUM DIOXIDE 16 g in 100 mL / OCTINOXATE 6.99 g in 100 mL TOPICAL CREAM [anna lotan Premium BB Cream SPF46 Medium Beige]


name: TITANIUM DIOXIDE 20 mg in 1 mL / ZINC OXIDE 170 mg in 1 mL TOPICAL CREAM [Mineral KidCreme SPF 50]


name: ZINC OXIDE 18 mg in 1 g TOPICAL CREAM [Prequel Sun Barrier Mineral Sunscreen Broad Spectrum SPF 50]


name: Nivea Intense Healing Moisture Body Cream


name: Audio-Video (Appendix P) and Audio-Only (Appendix T) Telemedicine Services Criteria


name: Use of Anti-Piracy Technology in CPT Professional 2024 Codebook


name: Multiple Evaluation and Management Services on the Same Date


name: New patient office or other outpatient visit with straightforward medical decision making, if using time, 15 minutes or more


name: Outpatient visit for evaluation and management of new patient, including medically appropriate examination and straightforward medical decision making. If using time at least 15 minutes of total time on the date of the encounter must be met.


name: Outpatient visit for evaluation and management of new patient, including medically appropriate history and straightforward medical decision making. If using time at least 15 minutes of total time on the date of the encounter must be met.


name: Outpatient visit for evaluation and management of new patient, including medically appropriate history, examination and straightforward medical decision making. If using time at least 15 minutes of total time on the date of the encounter must be met.


name: New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more


name: Outpatient visit for evaluation and management of new patient, including medically appropriate examination and low level of medical decision making. If using time, at least 30 minutes of total time on the date of the encounter must be met.


name: Outpatient visit for evaluation and management of new patient, including medically appropriate history and low level of medical decision making. If using time, at least 30 minutes of total time on the date of the encounter must be met.


name: Outpatient visit for evaluation and management of new patient, including medically appropriate history, examination and low level of medical decision making. If using time at least 30 minutes of total time on the date of the encounter must be met.


name: New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more


name: Outpatient visit for evaluation and management of new patient, including medically appropriate examination and moderate level of medical decision making. If using time, at least 45 minutes of total time on the date of the encounter must be met.


name: Outpatient visit for evaluation and management of new patient, including medically appropriate history and moderate level of medical decision making. If using time, at least 45 minutes of total time on the date of the encounter must be met.


name: Outpatient visit for evaluation and management of new patient, including medically appropriate history, examination and moderate level of medical decision making. If using time at least 45 minutes of total time on the date of the encounter must be met.


name: New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more


name: Outpatient visit for evaluation and management of new patient, including medically appropriate examination and high level of medical decision making. If using time, at least 60 minutes of total time on the date of the encounter must be met.


name: Outpatient visit for evaluation and management of new patient, including medically appropriate history and high level of medical decision making. If using total time, at least 60 minutes of total time on the date of the encounter must be met.


name: Outpatient visit for evaluation and management of new patient, including medically appropriate history, examination and high level of medical decision making. If using total time, at least 60 minutes of total time on the date of the encounter must be met.


name: Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more


name: Outpatient visit for evaluation and management of established patient, including medically appropriate examination and straightforward medical decision making. If using time, at least 10 minutes of total time on encounter date must be met.


name: Outpatient visit for evaluation and management of established patient, including medically appropriate history and straightforward medical decision making. If using time, at least 10 minutes of total time on the encounter date must be met.


name: Outpatient visit for evaluation and management of established patient, including medically appropriate history, examination and straightforward medical decision making. If using time, at least 10 minutes of total time on the encounter date must be met.


name: Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more


name: Outpatient visit for evaluation and management of established patient, including medically appropriate examination and low level of medical decision making. If using time, at least 20 minutes of total time on the date of the encounter must be met.


name: Outpatient visit for evaluation and management of established patient, including medically appropriate history and low level of medical decision making. If using time, at least 20 minutes of total time on the date of the encounter must be met.


name: Outpatient visit for evaluation and management of established patient, including medically appropriate history, examination and low level of medical decision making. If using time at least 20 minutes of total time on the date of the encounter must be met.


name: Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more


name: Outpatient visit for evaluation and management of established patient, including medically appropriate examination and moderate level of medical decision making. If using time, at least 30 minutes of total time on the date of the encounter must be met.


name: Outpatient visit for evaluation and management of established patient, including medically appropriate history and moderate level of medical decision making. If using time, at least 30 minutes of total time on the date of the encounter must be met.


name: Outpatient visit for evaluation and management of established patient, including medically appropriate history, examination and moderate level of medical decision making. If using time at least 30 minutes of total time on the date of the encounter must be met.


name: Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more


name: Outpatient visit for evaluation and management of established patient, including medically appropriate examination and high level of medical decision making. If using time, at least 40 minutes of total time on the date of the encounter must be met.


name: Outpatient visit for evaluation and management of established patient, including medically appropriate history and high level of medical decision making. If using time, at least 40 minutes of total time on the date of the encounter must be met.


name: Outpatient visit for evaluation and management of established patient, including medically appropriate history, examination and high level of medical decision making. If using time at least 40 minutes of total time on the date of the encounter must be met.


name: Initial nursing facility care with high level of medical decision making, per day, if using time, 50 minutes or more


name: Initial nursing facility care, per day, for evaluation and management of patient requiring medically appropriate examination and high level of medical decision making. If using time, at least 50 minutes total time on encounter date must be met.


name: Initial nursing facility care, per day, for evaluation and management of patient requiring medically appropriate history and examination and high level of medical decision making. If using time, at least 50 minutes total time on encounter date must be met.


name: Initial nursing facility care, per day, for evaluation and management of patient requiring medically appropriate history and high level of medical decision making. If using time, at least 50 minutes total time on encounter date must be met.


name: Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, 20 minutes or more


name: Subsequent nursing facility care, per day, for evaluation and management of patient requiring medically appropriate examination and low level of medical decision making. If using time, at least 20 minutes total time on encounter date must be met.


name: Subsequent nursing facility care, per day, for evaluation and management of patient requiring medically appropriate history and examination and low level of medical decision making. If using time, at least 20 minutes total time on encounter date must be met.


name: Subsequent nursing facility care, per day, for evaluation and management of patient requiring medically appropriate history and low level of medical decision making. If using time, at least 20 minutes total time on encounter date must be met.


name: Anterior thoracic vertebral body tethering, including thoracoscopy, when performed


name: Anterior thoracic vertebral body tethering, including thoracoscopy, when performed; up to 7 vertebral segments


name: Tethering of 7 or fewer middle spine bones


name: Anterior thoracic vertebral body tethering with thoracoscopy, 7 or fewer vertebral segments


name: Anterior thoracic vertebral body tethering, 7 or fewer vertebral segments


name: Anterior thoracic vertebral body tethering, including thoracoscopy, when performed; 8 or more vertebral segments


name: Tethering of 8 or more middle spine bones


name: Anterior thoracic vertebral body tethering with thoracoscopy, 8 or more vertebral segments


name: Anterior thoracic vertebral body tethering, 8 or more vertebral segments


name: Revision (eg, augmentation, division of tether), replacement, or removal of thoracic vertebral body tethering, including thoracoscopy, when performed


name: Revision, replacement, or removal of middle spine tethering


name: Augmentation of thoracic vertebral body tethering


name: Augmentation of thoracic vertebral body tethering with thoracoscopy


name: Division of thoracic vertebral body tethering


name: Division of thoracic vertebral body tethering with thoracoscopy


name: Removal of thoracic vertebral body tethering


name: Removal of thoracic vertebral body tethering with thoracoscopy


name: Replacement of thoracic vertebral body tethering


name: Replacement of thoracic vertebral body tethering with thoracoscopy


name: Revision of thoracic vertebral body tethering


name: Revision of thoracic vertebral body tethering with thoracoscopy


name: Arthrodesis, sacroiliac joint, percutaneous, with image guidance, including placement of intra-articular implant(s) (eg, bone allograft[s], synthetic device[s]), without placement of transfixation device


name: Fusion of pelvic joint including joint implant using imaging guidance


name: Percutaneous arthrodesis of sacroiliac joint with image guidance, including placement of bone allograft(s)


name: Percutaneous arthrodesis of sacroiliac joint with image guidance, including placement of intra-articular implant(s) (eg, bone allograft[s], synthetic device[s])


name: Percutaneous arthrodesis of sacroiliac joint with image guidance, including placement of synthetic device(s)


name: Correction of hallux vagus with bunionectomy and resection of proximal phalanx base


name: Correction of hallux vagus with bunionectomy and sesamoidectomy


name: Correction of hallux vagus with bunionectomy with sesamoidectomy and resection of proximal phalanx base


name: Correction of hallux vagus with bunionectomy and distal metatarsal osteotomy


name: Correction of hallux vagus with bunionectomy with sesamoidectomy and distal metatarsal osteotomy


name: Correction of hallux vagus with bunionectomy and proximal metatarsal osteotomy


name: Correction of hallux vagus with bunionectomy with sesamoidectomy and proximal metatarsal osteotomy


name: Correction of bunion with forefoot and midfoot bone fusion


name: Correction of hallux vagus with bunionectomy and first metatarsal and medial cuneiform joint arthrodesis


name: Correction of hallux vagus with bunionectomy, with sesamoidectomy and first metatarsal and medial cuneiform joint arthrodesis


name: Correction of hallux vagus with bunionectomy and proximal phalanx osteotomy


name: Correction of hallux vagus with bunionectomy with sesamoidectomy and proximal phalanx osteotomy


name: Correction of hallux vagus with bunionectomy and double osteotomy


name: Correction of hallux vagus with bunionectomy with sesamoidectomy and double osteotomy


name: Nasal/sinus endoscopy, surgical; with destruction by radiofrequency ablation, posterior nasal nerve


name: Destruction of nasal nerve by heat using an endoscope


name: Surgical nasal endoscopy with destruction of posterior nasal nerve by radiofrequency ablation


name: Surgical sinus endoscopy with destruction of posterior nasal nerve by radiofrequency ablation


name: Nasal/sinus endoscopy, surgical; with destruction by cryoablation, posterior nasal nerve


name: Destruction of nasal nerve by freezing using an endoscope


name: Surgical nasal endoscopy with destruction of posterior nasal nerve by cryoablation


name: Insertion of phrenic nerve stimulator system (pulse generator and stimulating lead[s]), including vessel catheterization, all imaging guidance, and pulse generator initial analysis with diagnostic mode activation, when performed


name: Insertion of phrenic nerve stimulator generator and stimulating lead(s)


name: Insertion of pulse generator and stimulating leads of phrenic nerve stimulator system


name: Insertion of pulse generator and stimulating leads of phrenic nerve stimulator system, including vessel catheterization, all imaging guidance, and pulse generator initial analysis with diagnostic mode activation


name: Insertion of phrenic nerve stimulator transvenous sensing lead (List separately in addition to code for primary procedure)


name: Insertion of phrenic nerve stimulator sensing lead


name: Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed


name: Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; system, including pulse generator and lead(s)


name: Removal of phrenic nerve stimulator generator and lead(s)


name: Removal of phrenic nerve stimulator system, including pulse generator and lead(s)


name: Removal of phrenic nerve stimulator system, including pulse generator and lead(s), including vessel catheterization, all imaging guidance, and interrogation and programming


name: Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous stimulation or sensing lead(s) only


name: Removal of phrenic nerve stimulator stimulation or sensing lead(s)


name: Removal of phrenic nerve stimulator sensing lead(s) only


name: Removal of phrenic nerve stimulator sensing lead(s) only, including vessel catheterization, all imaging guidance, and interrogation and programming


name: Removal of phrenic nerve stimulator transvenous stimulation lead(s) only


name: Removal of phrenic nerve stimulator transvenous stimulation lead(s) only, including vessel catheterization, all imaging guidance, and interrogation and programming


name: Removal of phrenic nerve stimulator transvenous stimulation or sensing lead(s) only


name: Removal of phrenic nerve stimulator transvenous stimulation or sensing lead(s) only, including vessel catheterization, all imaging guidance, and interrogation and programming


name: Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator only


name: Removal of phrenic nerve stimulator pulse generator


name: Removal of phrenic nerve stimulator pulse generator, including vessel catheterization, all imaging guidance, and interrogation and programming


name: Repositioning of phrenic nerve stimulator transvenous lead(s)


name: Repositioning of phrenic nerve stimulator lead(s)


name: Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed


name: Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator


name: Removal and replacement of phrenic nerve stimulator pulse generator


name: Removal and replacement of phrenic nerve stimulator pulse generator, including vessel catheterization, all imaging guidance, and interrogation and programming


name: Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous stimulation or sensing lead(s)


name: Removal and replacement of phrenic nerve stimulator stimulation or sensing leads


name: Removal and replacement of phrenic nerve stimulator sensing lead(s)


name: Removal and replacement of phrenic nerve stimulator sensing lead(s), including vessel catheterization, all imaging guidance, and interrogation and programming, when performed


name: Removal and replacement of phrenic nerve stimulator transvenous stimulation lead(s)


name: Removal and replacement of phrenic nerve stimulator transvenous stimulation lead(s), including vessel catheterization, all imaging guidance, and interrogation and programming, when performed


name: Removal and replacement of phrenic nerve stimulator transvenous stimulation or sensing lead(s)


name: Cystourethroscopy, with mechanical urethral dilation and urethral therapeutic drug delivery by drug-coated balloon catheter for urethral stricture or stenosis, male, including fluoroscopy, when performed


name: Drug delivery using a drug-coated balloon for male treatment of urethral stricture using an endoscope


name: Cystourethroscopy with mechanical urethral dilation and urethral therapeutic drug delivery by drug-coated balloon catheter for male urethral stricture or stenosis


name: Cystourethroscopy with mechanical urethral dilation and urethral therapeutic drug delivery by drug-coated balloon catheter for male urethral stricture or stenosis with fluoroscopy


name: Transcervical ablation of uterine fibroid(s), including intraoperative ultrasound guidance and monitoring, radiofrequency


name: Destruction of uterine fibroid(s) using heat with ultrasound guidance and monitoring


name: Insertion of skull-mounted cranial neurostimulator pulse generator or receiver, including craniectomy or craniotomy, when performed, with direct or inductive coupling, with connection to depth and/or cortical strip electrode array(s)


name: Insertion of skull-mounted cranial neurostimulator pulse generator or receiver


name: Insertion of skull-mounted cranial neurostimulator with direct coupling and connection to cortical strip electrode array(s)


name: Insertion of skull-mounted cranial neurostimulator with direct coupling and connection to depth strip electrode array(s)


name: Insertion of skull-mounted cranial neurostimulator with inductive coupling and connection to cortical strip electrode array(s)


name: Insertion of skull-mounted cranial neurostimulator with inductive coupling and connection to depth strip electrode array(s)


name: Insertion of skull-mounted cranial neurostimulator, including craniectomy, with direct coupling and connection to cortical strip electrode array(s)


name: Insertion of skull-mounted cranial neurostimulator, including craniectomy, with direct coupling and connection to depth strip electrode array(s)


name: Insertion of skull-mounted cranial neurostimulator, including craniectomy, with inductive coupling and connection to cortical strip electrode array(s)


name: Insertion of skull-mounted cranial neurostimulator, including craniectomy, with inductive coupling and connection to depth strip electrode array(s)


name: Insertion of skull-mounted cranial neurostimulator, including craniotomy, with direct coupling and connection to cortical strip electrode array(s)


name: Insertion of skull-mounted cranial neurostimulator, including craniotomy, with direct coupling and connection to depth strip electrode array(s)


name: Insertion of skull-mounted cranial neurostimulator, including craniotomy, with inductive coupling and connection to cortical strip electrode array(s)


name: Insertion of skull-mounted cranial neurostimulator, including craniotomy, with inductive coupling and connection to depth strip electrode array(s)


name: Revision or replacement of skull-mounted cranial neurostimulator pulse generator or receiver with connection to depth and/or cortical strip electrode array(s)


name: Revision or replacement of skull-mounted cranial neurostimulator pulse generator or receiver


name: Replacement of skull-mounted cranial neurostimulator pulse generator with connection to cortical strip electrode array


name: Replacement of skull-mounted cranial neurostimulator pulse generator with connection to depth strip electrode array


name: Replacement of skull-mounted cranial neurostimulator receiver with connection to cortical strip electrode array


name: Replacement of skull-mounted cranial neurostimulator receiver with connection to depth strip electrode array


name: Revision of skull-mounted cranial neurostimulator pulse generator with connection to cortical strip electrode array


name: Revision of skull-mounted cranial neurostimulator pulse generator with connection to depth strip electrode array


name: Revision of skull-mounted cranial neurostimulator receiver with connection to cortical strip electrode array


name: Revision of skull-mounted cranial neurostimulator receiver with connection to depth strip electrode array


name: Removal of skull-mounted cranial neurostimulator pulse generator or receiver with cranioplasty, when performed


name: Removal of skull-mounted cranial neurostimulator pulse generator or receiver


name: Removal of skull-mounted cranial neurostimulator pulse generator


name: Removal of skull-mounted cranial neurostimulator pulse generator with cranioplasty


name: Removal of skull-mounted cranial neurostimulator receiver


name: Removal of skull-mounted cranial neurostimulator with cranioplasty


name: Insertion or replacement of spinal neurostimulator generator or receiver


name: Insertion of spinal neurostimulator pulse generator, requiring pocket creation and connection between electrode array and pulse generator


name: Insertion of spinal neurostimulator receiver, requiring pocket creation and connection between electrode array and receiver


name: Replacement of spinal neurostimulator pulse generator, requiring pocket creation and connection between electrode array and pulse generator


name: Replacement of spinal neurostimulator receiver, requiring pocket creation and connection between electrode array and receiver


name: Removal or revision of spinal neurostimulator generator or receiver


name: Removal of implanted spinal neurostimulator pulse generator with detachable electrode array


name: Removal of implanted spinal neurostimulator receiver with detachable connection to electrode array


name: Revision of implanted neurostimulator receiver with detachable connection to electrode array


name: Revision of implanted spinal neurostimulator pulse generator with detachable connection to electrode array


name: Insertion or replacement of peripheral, sacral, or gastric neurostimulator generator or receiver


name: Insertion of gastric neurostimulator pulse generator, requiring pocket creation and connection between electrode array and pulse generator


name: Insertion of gastric neurostimulator receiver, requiring pocket creation and connection between electrode array and receiver


name: Insertion of peripheral neurostimulator pulse generator, requiring pocket creation and connection between electrode array and pulse generator


name: Insertion of peripheral neurostimulator receiver, requiring pocket creation and connection between electrode array and receiver


name: Insertion of sacral neurostimulator pulse generator, requiring pocket creation and connection between electrode array and pulse generator


name: Insertion of sacral neurostimulator receiver, requiring pocket creation and connection between electrode array and receiver


name: Replacement of gastric neurostimulator pulse generator, requiring pocket creation and connection between electrode array and pulse generator


name: Replacement of gastric neurostimulator receiver, requiring pocket creation and connection between electrode array and receiver


name: Replacement of peripheral neurostimulator pulse generator, requiring pocket creation and connection between electrode array and pulse generator


name: Replacement of peripheral neurostimulator receiver, requiring pocket creation and connection between electrode array and receiver


name: Replacement of sacral neurostimulator pulse generator, requiring pocket creation and connection between electrode array and pulse generator


name: Replacement of sacral neurostimulator receiver, requiring pocket creation and connection between electrode array and receiver


name: Removal or revision of a peripheral, sacral, or gastric neurostimulator pulse generator or receiver


name: Removal of gastric neurostimulator pulse generator, with detachable connection to electrode array


name: Removal of gastric neurostimulator receiver, with detachable connection to electrode array


name: Removal of peripheral neurostimulator pulse generator, with detachable connection to electrode array


name: Removal of peripheral neurostimulator receiver, with detachable connection to electrode array


name: Removal of sacral neurostimulator pulse generator, with detachable connection to electrode array


name: Removal of sacral neurostimulator receiver, with detachable connection to electrode array


name: Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator, including imaging guidance, when performed


name: Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator, including imaging guidance, when performed; initial electrode array


name: Insertion or replacement of a peripheral integrated neurostimulator initial electrode array


name: Insertion of peripheral nerve integrated neurostimulator percutaneous initial electrode array


name: Insertion of peripheral nerve integrated neurostimulator percutaneous initial electrode array, including imaging guidance


name: Replacement of peripheral nerve integrated neurostimulator percutaneous initial electrode array


name: Replacement of peripheral nerve integrated neurostimulator percutaneous initial electrode array, including imaging guidance


name: Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator, including imaging guidance, when performed; each additional electrode array (List separately in addition to code for primary procedure)


name: Insertion or replacement of a peripheral integrated neurostimulator each additional electrode array


name: Insertion of peripheral nerve integrated neurostimulator percutaneous each additional electrode array


name: Insertion of peripheral nerve integrated neurostimulator percutaneous each additional electrode array, including imaging guidance


name: Replacement of peripheral nerve integrated neurostimulator percutaneous each additional electrode array


name: Replacement of peripheral nerve integrated neurostimulator percutaneous each additional electrode array, including imaging guidance


name: Revision or removal of neurostimulator electrode array, peripheral nerve, with integrated neurostimulator


name: Revision or removal of a electrode array with an integrated neurostimulator


name: Removal of peripheral nerve neurostimulator electrode array, with integrated neurostimulator


name: Revision of peripheral nerve neurostimulator electrode array, with integrated neurostimulator


name: Suprachoroidal space injection of pharmacologic agent (separate procedure)


name: Injection of drug into the space between the cornea and retina in the eye


name: Noninvasive estimate of coronary fractional flow reserve (FFR) derived from augmentative software analysis of the data set from a coronary computed tomography angiography, with interpretation and report by a physician or other qualified health care professional


name: Ultrasound, intraoperative thoracic aorta (eg, epiaortic), diagnostic


name: Ultrasound of chest aorta during surgery


name: Diagnostic intraoperative epiaortic ultrasound


name: Intraoperative epicardial cardiac ultrasound (ie, echocardiography) for congenital heart disease, diagnostic


name: Intraoperative epicardial cardiac ultrasound (ie, echocardiography) for congenital heart disease, diagnostic; including placement and manipulation of transducer, image acquisition, interpretation and report


name: Ultrasound of heart during surgery to evaluate for congenital heart disease, including placement and manipulation of transducer, image acquisition, and interpretation and report of results


name: Intraoperative epicardial cardiac ultrasound (ie, echocardiography) for congenital heart disease, diagnostic; placement, manipulation of transducer, and image acquisition only


name: Ultrasound of heart during surgery to evaluate for congenital heart disease, including placement and manipulation of transducer and image acquisition


name: Diagnostic intraoperative epicardial cardiac echocardiography, placement, manipulation of transducer, and image acquisition only


name: Intraoperative epicardial cardiac ultrasound (ie, echocardiography) for congenital heart disease, diagnostic; interpretation and report only


name: Ultrasound of heart during surgery to evaluate for congenital heart disease, interpretation and report of results only


name: AFF2 (ALF transcription elongation factor 2 [FMR2]) (eg, fragile X intellectual disability 2 [FRAXE]) gene analysis


name: AF2/FMR2 gene analysis for detection of expanded alleles


name: Fragile X intellectual disability gene analysis for detection of abnormal alleles


name: Fragile X intellectual disability gene analysis for detection of expanded alleles


name: AF2/FMR2 gene analysis for evaluation of expanded size and methylation status of alleles


name: Fragile X intellectual disability gene analysis for characterization of alleles


name: Fragile X intellectual disability gene analysis for evaluation of expanded size and methylation status of alleles


name: FMR1 (fragile X messenger ribonucleoprotein 1) (eg, fragile X syndrome, X-linked intellectual disability [XLID]) gene analysis


name: Gene analysis (fragile X syndrome, X-linked intellectual disability) for detection of abnormal alleles


name: FMR1 gene analysis evaluation to detect expanded alleles


name: Fragile X syndrome gene analysis to detect abnormal alleles


name: Fragile X syndrome gene analysis to detect expanded alleles


name: X-linked intellectual gene analysis to detect abnormal alleles


name: X-linked intellectual gene analysis to detect expanded alleles


name: Gene analysis (fragile X syndrome, X-linked intellectual disability) for characterization of alleles


name: FMR1 gene analysis for evaluation of expanded size and promoter methylation status of alleles


name: Fragile X ribonucleoprotein 1 gene analysis evaluation of expanded size and promoter methylation status of alleles


name: Fragile X syndrome gene analysis for characterization of alleles


name: Fragile X syndrome gene analysis for evaluation of expanded size and promoter methylation status of alleles


name: X-linked intellectual disability gene analysis for characterization of alleles


name: X-linked intellectual disability gene analysis for evaluation of expanded size and promoter methylation status of alleles


name: Molecular pathology procedure level 4 genetic analysis


name: Level 4 molecular analysis -targeted sequence analysis of exon 7 of fibroblast growth factor receptor 3 (FGFR3) for evaluation of isolated craniosynostosis


name: Level 4 molecular pathology procedure - Analysis of more than 10 amplicons using multiplex PCR in 2 or more independent reactions


name: Level 4 molecular pathology procedure - Analysis of single exon by DNA sequence analysis


name: Level 4 molecular pathology procedure - Angiogenin, ribonuclease, RNase A family (ANG) full gene sequence analysis


name: Level 4 molecular pathology procedure - Coagulation factor VIII (F8), inversion analysis of intron 1


name: Level 4 molecular pathology procedure - Coagulation factor VIII (F8), inversion analysis of intron 22A


name: Level 4 molecular pathology procedure - Colton blood group (AQP1) antigen gene analysis for detection of common variants


name: Level 4 molecular pathology procedure - Colton blood group (AQP1) antigen gene analysis for detection of common variants for evaluation of hemolytic disease of the fetus


name: Level 4 molecular pathology procedure - Colton blood group (AQP1) antigen gene analysis for detection of common variants for evaluation of hemolytic disease of the newborn


name: Level 4 molecular pathology procedure - Colton blood group (AQP1) antigen gene analysis for detection of common variants for evaluation of hemolytic transfusion reactions


name: Level 4 molecular pathology procedure - Colton blood group (AQP1) antigen gene analysis for detection of common variants for evaluation of sickle-cell disease


name: Level 4 molecular pathology procedure - Colton blood group (AQP1) antigen gene analysis for detection of common variants for evaluation of thalassemia


name: Level 4 molecular pathology procedure - Deletion analysis Rh blood group, D antigen (RHD) of pseudogene for evaluation of hemolytic disease of the newborn


name: Level 4 molecular pathology procedure - Deletion analysis of Epithelial cell adhesion molecule (EPCAM) for evaluation of Lynch syndrome


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exon 4 for Rh maternal/fetal compatibility


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exon 4 for evaluation of hemolytic disease of the fetus


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exon 4 for evaluation of hemolytic disease of the newborn


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exon 4 performed on cell-free fetal DNA in maternal blood for evaluation of Rh maternal/fetal compatibility


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exon 4 performed on cell-free fetal DNA in maternal blood for evaluation of hemolytic disease of the fetus


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exon 4 performed on cell-free fetal DNA in maternal blood for evaluation of hemolytic disease of the newborn


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exon 5 for evaluation of Rh maternal/fetal compatibility


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exon 5 for evaluation of hemolytic disease of the fetus


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exon 5 for evaluation of hemolytic disease of the newborn


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exon 5 performed on cell-free fetal DNA in maternal blood for evaluation of Rh maternal/fetal compatibility


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exon 5 performed on cell-free fetal DNA in maternal blood for evaluation of hemolytic disease of the fetus


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exon 5 performed on cell-free fetal DNA in maternal blood for evaluation of hemolytic disease of the newborn


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exon 7 for evaluation of Rh maternal/fetal compatibility


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exon 7 for evaluation of hemolytic disease of the fetus


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exon 7 for evaluation of hemolytic disease of the newborn


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exon 7 performed on cell-free fetal DNA in maternal blood for evaluation of Rh maternal/fetal compatibility


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exon 7 performed on cell-free fetal DNA in maternal blood for evaluation of hemolytic disease of the fetus


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exon 7 performed on cell-free fetal DNA in maternal blood for evaluation of hemolytic disease of the newborn


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exons 4, 5, 7, and pseudogene for evaluation of Rh maternal/fetal compatibility


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exons 4, 5, 7, and pseudogene for evaluation of hemolytic disease of the fetus


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exons 4, 5, 7, and pseudogene for evaluation of hemolytic disease of the newborn


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exons 4, 5, 7, and pseudogene performed on cell-free fetal DNA in maternal blood for evaluation of Rh maternal/fetal compatibility


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exons 4, 5, 7, and pseudogene performed on cell-free fetal DNA in maternal blood for evaluation of hemolytic disease of the fetus


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) exons 4, 5, 7, and pseudogene performed on cell-free fetal DNA in maternal blood for evaluation of hemolytic disease of the newborn


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) pseudogene for evaluation of Rh maternal/fetal compatibility


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) pseudogene for evaluation of hemolytic disease of the fetus


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) pseudogene performed on cell-free fetal DNA in maternal blood for evaluation of Rh maternal/fetal compatibility


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) pseudogene performed on cell-free fetal DNA in maternal blood for evaluation of hemolytic disease of the fetus


name: Level 4 molecular pathology procedure - Deletion analysis of Rh blood group, D antigen (RHD) pseudogene performed on cell-free fetal DNA in maternal blood for evaluation of hemolytic disease of the newborn


name: Level 4 molecular pathology procedure - Deletion analysis of SH2 domain containing 1A (SH2D1A) for evaluation of X-linked lymphoproliferative syndrome


name: Level 4 molecular pathology procedure - Deletion analysis of Von Hippel-Lindau tumor suppressor (VHL) for evaluation of Hippel-Lindau familial cancer syndrome


name: Level 4 molecular pathology procedure - Deletion analysis of aristaless-related homeobox (ARX) for evaluation of X-linked intellectual disability


name: Level 4 molecular pathology procedure - Deletion analysis of aristaless-related homeobox (ARX) for evaluation of X-linked lissencephaly with ambiguous genitalia


name: Level 4 molecular pathology procedure - Deletion analysis of paired-like homeobox 2b (PHOX2B)for evaluation of congenital central hypoventilation syndrome


name: Level 4 molecular pathology procedure - Deletion analysis of twist homolog 1 [Drosophila] (TWIST1) for evaluation of Saethre-Chotzen syndrome


name: Level 4 molecular pathology procedure - Deletion and duplication analysis of SH2 domain containing 1A (SH2D1A) for evaluation of X-linked lymphoproliferative syndrome


name: Level 4 molecular pathology procedure - Deletion and duplication analysis of Von Hippel-Lindau tumor suppressor (VHL) for evaluation of Hippel-Lindau familial cancer syndrome


name: Level 4 molecular pathology procedure - Deletion and duplication analysis of aristaless-related homeobox (ARX) for evaluation of X-linked intellectual disability


name: Level 4 molecular pathology procedure - Deletion and duplication analysis of twist homolog 1 [Drosophila] (TWIST1)for evaluation of Saethre-Chotzen syndrome


name: Level 4 molecular pathology procedure - Deletion and duplication of aristaless-related homeobox (ARX) analysis for evaluation of X-linked lissencephaly with ambiguous genitalia


name: Level 4 molecular pathology procedure - Diego blood group (SLC4A1) antigen gene analysis for detection of common variants


name: Level 4 molecular pathology procedure - Diego blood group (SLC4A1) antigen gene analysis for detection of common variants for evaluation of hemolytic disease of the fetus


name: Level 4 molecular pathology procedure - Diego blood group (SLC4A1) antigen gene analysis for detection of common variants for evaluation of hemolytic transfusion reactions


name: Level 4 molecular pathology procedure - Diego blood group (SLC4A1) antigen gene analysis for detection of common variants for evaluation of sickle-cell disease


name: Level 4 molecular pathology procedure - Diego blood group (SLC4A1) antigen gene analysis for detection of common variants for evaluation of thalassemia


name: Level 4 molecular pathology procedure - Diego blood group (SLC4A1) antigen gene analysis for detection of common variants for hemolytic disease of the newborn


name: Level 4 molecular pathology procedure - Dombrock blood group (ART4) antigen gene analysis for detection of common variants


name: Level 4 molecular pathology procedure - Dombrock blood group (ART4) antigen gene analysis for detection of common variants for evaluation of hemolytic disease of the fetus


name: Level 4 molecular pathology procedure - Dombrock blood group (ART4) antigen gene analysis for detection of common variants for evaluation of hemolytic disease of the newborn


name: Level 4 molecular pathology procedure - Dombrock blood group (ART4) antigen gene analysis for detection of common variants for evaluation of hemolytic transfusion reactions


name: Level 4 molecular pathology procedure - Dombrock blood group (ART4) antigen gene analysis for detection of common variants for evaluation of sickle-cell disease


name: Level 4 molecular pathology procedure - Dombrock blood group (ART4) antigen gene analysis for detection of common variants for evaluation of thalassemia


name: Level 4 molecular pathology procedure - Duffy blood group (DARC) antigen gene analysis for detection of common variants


name: Level 4 molecular pathology procedure - Duplication analysis of SH2 domain containing 1A (SH2D1A) for evaluation of X-linked lymphoproliferative syndrome


name: Level 4 molecular pathology procedure - Duplication analysis of Von Hippel-Lindau tumor suppressor (VHL) for evaluation of Hippel-Lindau familial cancer syndrome


name: Level 4 molecular pathology procedure - Duplication analysis of aristaless-related homeobox (ARX) for evaluation of X-linked intellectual disability


name: Level 4 molecular pathology procedure - Duplication analysis of aristaless-related homeobox (ARX) for evaluation of X-linked lissencephaly with ambiguous genitalia


name: Level 4 molecular pathology procedure - Duplication analysis of epithelial cell adhesion molecule (EPCAM) for evaluation of Lynch syndrome


name: Level 4 molecular pathology procedure - Duplication analysis of paired-like homeobox 2b (PHOX2B)for evaluation of congenital central hypoventilation syndrome


name: Level 4 molecular pathology procedure - Duplication analysis of twist homolog 1 [Drosophila] (TWIST1) for evaluation of Saethre-Chotzen syndrome


name: Level 4 molecular pathology procedure - Duplication and deletion analysis of epithelial cell adhesion molecule (EPCAM) for evaluation of Lynch syndrome


name: Level 4 molecular pathology procedure - Duplication and deletion analysis of paired-like homeobox 2b (PHOX2B) for evaluation of congenital central hypoventilation syndrome


name: Level 4 molecular pathology procedure - Duplication and deletion analysis of variants of 2-5 exons


name: Level 4 molecular pathology procedure - Exon 2 sequence analysis of v-Ha-ras Harvey rat sarcoma viral oncogene homolog (HRAS) for evaluation of Costello syndrome


name: Level 4 molecular pathology procedure - Full gene sequence analysis of mitochondrially encoded 12S RNA (MT-RNR1) for evaluation of nonsyndromic hearing loss


name: Level 4 molecular pathology procedure - Full gene sequence analysis of phospholamban (PLN) for evaluation of dilated cardiomyopathy


name: Level 4 molecular pathology procedure - Full gene sequence analysis of potassium inwardly-rectifying channel, subfamily J, member 11 (KCNJ11for evaluation of familial hyperinsulinism


name: Level 4 molecular pathology procedure - Full gene sequence analysis of potassium inwardly-rectifying channel, subfamily J, member 2 (KCNJ2) for evaluation of Andersen-Tawil syndrome


name: Level 4 molecular pathology procedure - Full gene sequence of NHL repeat containing 1 (NHLRC1) for evaluation of progressive myoclonal epilepsy


name: Level 4 molecular pathology procedure - Gene analysis for common deletions of deleted in azoospermia and sex determining region Y (DAZ/SRY) for evaluation of male infertility


name: Level 4 molecular pathology procedure - Gene analysis for detection of AZFa deletion of deleted in azoospermia and sex determining region Y (DAZ/SRY) for evaluation of male infertility


name: Level 4 molecular pathology procedure - Gene analysis for detection of AZFb deletion for evaluation of male infertility


name: Level 4 molecular pathology procedure - Gene analysis for detection of AZFc deletion of deleted in azoospermia and sex determining region Y (DAZ/SRY) for evaluation of male infertility


name: Level 4 molecular pathology procedure - Gene analysis for detection of AZFd deletion of deleted in azoospermia and sex determining region Y (DAZ/SRY) for evaluation of male infertility


name: Level 4 molecular pathology procedure - Gene analysis of MHC class I polypeptide-related sequence A (MICA) for detection of *001 variant in solid organ transplantation


name: Level 4 molecular pathology procedure - Gene analysis of MHC class I polypeptide-related sequence A (MICA) for detection of *002 variant in solid organ transplantation


name: Level 4 molecular pathology procedure - Gene analysis of MHC class I polypeptide-related sequence A (MICA) for detection of common variants in solid organ transplantation


name: Level 4 molecular pathology procedure - Gene analysis of guanine nucleotide-binding protein G(q) subunit alpha (GNAQ) for detection of Q209 variant for evaluation of uveal melanoma


name: Level 4 molecular pathology procedure - Gene analysis of guanine nucleotide-binding protein G(q) subunit alpha (GNAQ) for detection of R183 and Q209 variants for evaluation of uveal melanoma


name: Level 4 molecular pathology procedure - Gene analysis of guanine nucleotide-binding protein G(q) subunit alpha (GNAQ) for detection of R183 variant for evaluation of uveal melanoma


name: Level 4 molecular pathology procedure - Gene analysis of guanine nucleotide-binding protein G(q) subunit alpha (GNAQ) for detection of common variants for evaluation of uveal melanoma


name: Level 4 molecular pathology procedure - Human erythrocyte antigen gene analysis for detection of common variants associated with hemolytic disease of the fetus


name: Level 4 molecular pathology procedure - Human erythrocyte antigen gene analysis for detection of common variants associated with hemolytic disease of the newborn


name: Level 4 molecular pathology procedure - Human erythrocyte antigen gene analysis for detection of common variants associated with hemolytic transfusion reactions


name: Level 4 molecular pathology procedure - Human erythrocyte antigen gene analysis for detection of common variants associated with sickle-cell disease


name: Level 4 molecular pathology procedure - Human erythrocyte antigen gene analysis for detection of common variants associated with thalassemia


name: Level 4 molecular pathology procedure - Inversion analysis of intron 1 and intron 22A of coagulation factor VIII (F8) for evaluation of hemophilia A


name: Level 4 molecular pathology procedure - Inversion analysis of intron 1 of coagulation factor VIII (F8) for evaluation of hemophilia A


name: Level 4 molecular pathology procedure - Inversion analysis of intron 22A of coagulation factor VIII (F8) for evaluation of hemophilia A


name: Level 4 molecular pathology procedure - Kell blood group (KEL) antigen analysis for detection of common variants


name: Level 4 molecular pathology procedure - Kell blood group (KEL) antigen analysis for detection of common variants for evaluation of hemolytic disease of the fetus


name: Level 4 molecular pathology procedure - Kell blood group (KEL) antigen analysis for detection of common variants for evaluation of hemolytic disease of the newborn


name: Level 4 molecular pathology procedure - Kell blood group (KEL) antigen analysis for detection of common variants for evaluation of hemolytic transfusion reactions


name: Level 4 molecular pathology procedure - Kell blood group (KEL) antigen analysis for detection of common variants for evaluation of sickle-cell disease


name: Level 4 molecular pathology procedure - Kell blood group (KEL) antigen analysis for detection of common variants for evaluation of thalassemia


name: Level 4 molecular pathology procedure - Kidd blood group (SLC14A1) antigen gene analysis for detection of common variants


name: Level 4 molecular pathology procedure - Kidd blood group (SLC14A1) antigen gene analysis for detection of common variants for the evaluation of hemolytic disease of the fetus


name: Level 4 molecular pathology procedure - Kidd blood group (SLC14A1) antigen gene analysis for detection of common variants for the evaluation of hemolytic disease of the newborn


name: Level 4 molecular pathology procedure - Kidd blood group (SLC14A1) antigen gene analysis for detection of common variants for the evaluation of hemolytic transfusion reactions


name: Level 4 molecular pathology procedure - Kidd blood group (SLC14A1) antigen gene analysis for detection of common variants for the evaluation of sickle-cell disease


name: Level 4 molecular pathology procedure - Kidd blood group (SLC14A1) antigen gene analysis for detection of common variants for the evaluation of thalassemia


name: Level 4 molecular pathology procedure - Landsteiner-Wiener blood group (ICAM4) antigen gene analysis for detection of common variants


name: Level 4 molecular pathology procedure - Landsteiner-Wiener blood group (ICAM4) antigen gene analysis for detection of common variants for evaluation of hemolytic disease of the fetus


name: Level 4 molecular pathology procedure - Landsteiner-Wiener blood group (ICAM4) antigen gene analysis for detection of common variants for evaluation of hemolytic disease of the newborn


name: Level 4 molecular pathology procedure - Landsteiner-Wiener blood group (ICAM4) antigen gene analysis for detection of common variants for evaluation of hemolytic transfusion reactions


name: Level 4 molecular pathology procedure - Landsteiner-Wiener blood group (ICAM4) antigen gene analysis for detection of common variants for evaluation of sickle-cell disease


name: Level 4 molecular pathology procedure - Landsteiner-Wiener blood group (ICAM4) antigen gene analysis for detection of common variants for evaluation of thalassemia


name: Level 4 molecular pathology procedure - Lutheran blood group (BCAM) antigen gene analysis for detection of common variants


name: Level 4 molecular pathology procedure - Lutheran blood group (BCAM) antigen gene analysis for detection of common variants for evaluation of hemolytic disease of the fetus


name: Level 4 molecular pathology procedure - Lutheran blood group (BCAM) antigen gene analysis for detection of common variants for evaluation of hemolytic disease of the newborn


name: Level 4 molecular pathology procedure - Lutheran blood group (BCAM) antigen gene analysis for detection of common variants for evaluation of hemolytic transfusion reactions


name: Level 4 molecular pathology procedure - Lutheran blood group (BCAM) antigen gene analysis for detection of common variants for evaluation of sickle-cell disease


name: Level 4 molecular pathology procedure - Lutheran blood group (BCAM) antigen gene analysis for detection of common variants for evaluation of thalassemia


name: Level 4 molecular pathology procedure - MNS blood group (GYPA, GYPB, GYPE) antigen gene analysis for detection of common variants


name: Level 4 molecular pathology procedure - MNS blood group (GYPA, GYPB, GYPE) antigen gene analysis for detection of common variants for evaluation of hemolytic disease of the fetus


name: Level 4 molecular pathology procedure - MNS blood group (GYPA, GYPB, GYPE) antigen gene analysis for detection of common variants for evaluation of hemolytic disease of the newborn


name: Level 4 molecular pathology procedure - MNS blood group (GYPA, GYPB, GYPE) antigen gene analysis for detection of common variants for evaluation of hemolytic transfusion reactions


name: Level 4 molecular pathology procedure - MNS blood group (GYPA, GYPB, GYPE) antigen gene analysis for detection of common variants for evaluation of sickle-cell disease


name: Level 4 molecular pathology procedure - MNS blood group (GYPA, GYPB, GYPE) antigen gene analysis for detection of common variants for evaluation of thalassemia


name: Level 4 molecular pathology procedure - Mutation scanning of 2-5 exons


name: Level 4 molecular pathology procedure - Potassium inwardly-rectifying channel, subfamily J, member 11 (KCNJ11) full gene sequence analysis


name: Level 4 molecular pathology procedure - Potassium inwardly-rectifying channel, subfamily J, member 2 (KCNJ2) full gene sequence analysis


name: Level 4 molecular pathology procedure - Potassium voltage-gated channel, Shaw-related subfamily, member 3 (KCNC3) targeted sequence analysis


name: Level 4 molecular pathology procedure - Potassium voltage-gated channel, Shaw-related subfamily, member 3 (KCNC3) targeted sequence analysis of exon 2


name: Level 4 molecular pathology procedure - Rh blood group, CcEe antigens (RHCE) antigen gene analysis for detection of common variants


name: Level 4 molecular pathology procedure - Rh blood group, CcEe antigens (RHCE) antigen gene analysis for detection of common variants for evaluation of hemolytic disease of the fetus


name: Level 4 molecular pathology procedure - Rh blood group, CcEe antigens (RHCE) antigen gene analysis for detection of common variants for evaluation of hemolytic disease of the newborn


name: Level 4 molecular pathology procedure - Rh blood group, CcEe antigens (RHCE) antigen gene analysis for detection of common variants for evaluation of hemolytic transfusion reactions


name: Level 4 molecular pathology procedure - Rh blood group, CcEe antigens (RHCE) antigen gene analysis for detection of common variants for evaluation of sickle-cell disease


name: Level 4 molecular pathology procedure - Rh blood group, CcEe antigens (RHCE) antigen gene analysis for detection of common variants for evaluation of thalassemia


name: Level 4 molecular pathology procedure - Rh blood group, D antigen (RHD) deletion analysis of exon 4 performed on cell-free fetal DNA in maternal blood


name: Level 4 molecular pathology procedure - Rh blood group, D antigen (RHD) deletion analysis of exon 5 performed on cell-free fetal DNA in maternal blood


name: Level 4 molecular pathology procedure - Rh blood group, D antigen (RHD) deletion analysis of exon 7 performed on cell-free fetal DNA in maternal blood


name: Level 4 molecular pathology procedure - Rh blood group, D antigen (RHD) deletion analysis of exons 4. 5,7, and pseudogene performed on cell-free fetal DNA in maternal blood


name: Level 4 molecular pathology procedure - Rh blood group, D antigen (RHD) deletion analysis of pseudogene performed on cell-free fetal DNA in maternal blood


name: Level 4 molecular pathology procedure - Scianna blood group (ERMAP) antigen gene analysis for detection of common variants


name: Level 4 molecular pathology procedure - Scianna blood group (ERMAP) antigen gene analysis for detection of common variants for evaluation of hemolytic disease of the fetus


name: Level 4 molecular pathology procedure - Scianna blood group (ERMAP) antigen gene analysis for detection of common variants for evaluation of hemolytic disease of the newborn


name: Level 4 molecular pathology procedure - Scianna blood group (ERMAP) antigen gene analysis for detection of common variants for evaluation of hemolytic transfusion reactions


name: Level 4 molecular pathology procedure - Scianna blood group (ERMAP) antigen gene analysis for detection of common variants for evaluation of sickle-cell disease


name: Level 4 molecular pathology procedure - Scianna blood group (ERMAP) antigen gene analysis for detection of common variants for evaluation of thalassemia


name: Level 4 molecular pathology procedure - Targeted sequence analysis of DNA (cytosine-5-)-methyltransferase 3 alpha (DNMT3A) for evaluation of acute myeloid leukemia


name: Level 4 molecular pathology procedure - Targeted sequence analysis of exon 11 for detection of c.1686delT variant of carboxyl ester lipase (bile salt-stimulated lipase) (CEL) for evaluation of maturity-onset diabetes of the young (MODY)


name: Level 4 molecular pathology procedure - Targeted sequence analysis of exon 11 for detection of c.1785delC and c.1686delT variants of carboxyl ester lipase (bile salt-stimulated lipase) (CEL) for evaluation of maturity-onset diabetes of the young (MODY)


name: Level 4 molecular pathology procedure - Targeted sequence analysis of exon 11 of Carboxyl ester lipase (bile salt-stimulated lipase) (CEL) for evaluation of maturity-onset diabetes of the young (MODY)


name: Level 4 molecular pathology procedure - Targeted sequence analysis of exon 3 of catenin (cadherin-associated protein), beta 1, 88kDa (CTNNB1) for evaluation of Desmoid tumor(s)


name: Level 4 molecular pathology procedure - Targeted sequence analysis of exon 9 of coagulation factor XII (F12) for evaluation of Factor XII deficiency


name: Level 4 molecular pathology procedure - Targeted sequence analysis of exon 9 of coagulation factor XII (F12) for evaluation of angioedema, hereditary, type III


name: Level 4 molecular pathology procedure - Targeted sequence analysis of fibroblast growth factor receptor 3 (FGFR3) for evaluation of isolated craniosynostosis


name: Level 4 molecular pathology procedure - Targeted sequence analysis of potassium voltage-gated channel, Shaw-related subfamily, member 3 (KCNC3) exon 2 for evaluation of spinocerebellar ataxia


name: Level 4 molecular pathology procedure - Targeted sequence analysis of potassium voltage-gated channel, Shaw-related subfamily, member 3 (KCNC3) for evaluation of spinocerebellar ataxia


name: Level 4 molecular pathology procedure - Targeted sequence analysis of ubiquitin-like modifier activating enzyme 1 (UBA1) exon 15 for evaluation of X-linked spinal muscular atrophy


name: Level 4 molecular pathology procedure - Targeted sequence analysis of ubiquitin-like modifier activating enzyme 1 (UBA1) for evaluation of X-linked spinal muscular atrophy


name: Level 4 molecular pathology procedure - Targeted sequence analysis of von Willebrand factor (VWF) exon 28 for evaluation of von Willebrand disease type 2B


name: Level 4 molecular pathology procedure - Targeted sequence analysis of von Willebrand factor (VWF) for evaluation of von Willebrand disease type 2A


name: Level 4 molecular pathology procedure - Targeted sequence analysis of von Willebrand factor (VWF) for evaluation of von Willebrand disease type 2B


name: Level 4 molecular pathology procedure - Targeted sequence analysis of von Willebrand factor (VWF) for evaluation of von Willebrand disease type 2M


name: Level 4 molecular pathology procedure - Targeted sequence analysis of von Willebrand factor (VWF)exon 28 for evaluation of von Willebrand disease type 2A


name: Level 4 molecular pathology procedure - full gene sequence analysis of angiogenin, ribonuclease, RNase A family, 5 (ANG) for evaluation of amyotrophic lateral sclerosis


name: Level 4 molecular pathology procedure - full gene sequence analysis of phospholamban (PLN) for evaluation of hypertrophic cardiomyopathy


name: Level 4 molecular pathology procedure - v-Ha-ras Harvey rat sarcoma viral oncogene homolog (HRAS) exon 2 sequence analysis


name: Level 4 molecular pathology procedure -Full gene sequence analysis of melanocortin 4 receptor (MC4R) for evaluation of obesity


name: Level 4 molecular pathology procedure -Full gene sequence analysis of mitochondrially encoded tRNA serine 1 (MT-TS1) for evaluation of nonsyndromic hearing loss


name: Level 4 molecular pathology procedure -Genotyping of killer cell immunoglobulin-like receptor (KIR) genes in hematopoietic stem cell transplantation


name: Level 4 molecular pathology procedure -Targeted sequence analysis of catenin (cadherin-associated protein), beta 1, 88kDa (CTNNB1) for evaluation of Desmoid tumor(s)


name: Level 4 molecular pathology procedure -Targeted sequence analysis of exon 11 for detection of c.1785delC variant of carboxyl ester lipase (bile salt-stimulated lipase) (CEL) for evaluation of maturity-onset diabetes of the young (MODY)


name: Level 4 molecular pathology procedure -Targeted sequence analysis of exon 23 of DNA (cytosine-5-)-methyltransferase 3 alpha (DNMT3A) for evaluation of acute myeloid leukemia


name: Level 4 molecular pathology procedure -full gene sequence analysis of gap junction protein, beta 1 (GJB1) for evaluation of X-linked Charcot-Marie-Tooth


name: Level 4 molecular pathology procedure- Male infertility gene analysis for detection of AZFa, AZFb, AZFc, and AZFd deletions of deleted in azoospermia and sex determining region Y (DAZ/SRY) for evaluation of male infertility


name: Molecular pathology procedure level 5 genetic analysis


name: Level 4 molecular pathology procedure - Serine/threonine kinase 11 (STK11) duplication analysis


name: Level 5 molecular pathology analysis - Solute carrier family 25 (carnitine/acylcarnitine translocase), member 20 (SLC25A20) deletion analysis


name: Level 5 molecular pathology procedure - - Full gene sequence of aristaless related homeobox (ARX) for evaluation of X-linked intellectual disability


name: Level 5 molecular pathology procedure - Analysis of 2-5 exons by DNA sequence analysis


name: Level 5 molecular pathology procedure - Characterization of a dynamic mutation disorder/triplet repeat by Southern blot analysis


name: Level 5 molecular pathology procedure - Deletion analysis of HNF1 homeobox B (HBB) deletion analysis for evaluation of maturity-onset diabetes of the young (MODY)


name: Level 5 molecular pathology procedure - Deletion analysis of MpV17 mitochondrial inner membrane protein (MPV17) for evaluation of mitochondrial DNA depletion syndrome


name: Level 5 molecular pathology procedure - Deletion analysis of emerin (EMD) for evaluation of Emery-Dreifuss muscular dystrophy


name: Level 5 molecular pathology procedure - Deletion analysis of multiple endocrine neoplasia I (MEN1) for evaluation of Werner syndrome


name: Level 5 molecular pathology procedure - Deletion analysis of multiple endocrine neoplasia I (MEN1) for evaluation of multiple endocrine neoplasia type 1


name: Level 5 molecular pathology procedure - Deletion analysis of neuroligin 4, X-linked (NLGN4X) for the evaluation of autism spectrum disorders


name: Level 5 molecular pathology procedure - Deletion analysis of polyglutamine binding protein 1 (PQBP1) for evaluation of Renpenning syndrome


name: Level 5 molecular pathology procedure - Deletion analysis of proteolipid protein 1 (PLP1) for evaluation of Pelizaeus-Merzbacher disease


name: Level 5 molecular pathology procedure - Deletion analysis of proteolipid protein 1 (PLP1) for evaluation of spastic paraplegia


name: Level 5 molecular pathology procedure - Deletion analysis of sarcoglycan, gamma (35kDa dystrophin-associated glycoprotein) (SGCG) for the evaluation of limb-girdle muscular dystrophy


name: Level 5 molecular pathology procedure - Deletion analysis of serine/threonine kinase 11 (STK11) for the evaluation of Peutz-Jeghers syndrome


name: Level 5 molecular pathology procedure - Deletion analysis of solute carrier family 16, member 2 (thyroid hormone transporter) (SLC16A2) for the evaluation of Allan-Herndon-Dudley syndrome


name: Level 5 molecular pathology procedure - Deletion analysis of solute carrier family 16, member 2 (thyroid hormone transporter) (SLC16A2) for the evaluation of specific thyroid hormone cell transporter deficiency


name: Level 5 molecular pathology procedure - Deletion analysis of solute carrier family 25 (carnitine/acylcarnitine translocase), member 20 (SLC25A20) for evaluation of carnitine-acylcarnitine translocase deficiency


name: Level 5 molecular pathology procedure - Deletion analysis of succinate dehydrogenase complex, subunit C, integral membrane protein, 15kDa (SDHC) for the evaluation of hereditary paraganglioma-pheochromocytoma syndrome


name: Level 5 molecular pathology procedure - Deletion analysis of zinc finger E-box binding homeobox 2 (ZEB2) for evaluation of Mowat-Wilson syndrome


name: Level 5 molecular pathology procedure - Deletion and duplication analysis of HNF1 homeobox B (HBB) for evaluation of maturity-onset diabetes of the young (MODY)


name: Level 5 molecular pathology procedure - Deletion and duplication analysis of MpV17 mitochondrial inner membrane protein (MPV17) for evaluation of mitochondrial DNA depletion syndrome


name: Level 5 molecular pathology procedure - Deletion and duplication analysis of emerin (EMD) for evaluation of Emery-Dreifuss muscular dystrophy


name: Level 5 molecular pathology procedure - Deletion and duplication analysis of multiple endocrine neoplasia I (MEN1) for evaluation of Werner syndrome


name: Level 5 molecular pathology procedure - Deletion and duplication analysis of multiple endocrine neoplasia I (MEN1) for evaluation of multiple endocrine neoplasia type 1


name: Level 5 molecular pathology procedure - Deletion and duplication analysis of neuroligin 4, X-linked (NLGN4X) for the evaluation of autism spectrum disorders


name: Level 5 molecular pathology procedure - Deletion and duplication analysis of polyglutamine binding protein 1 (PQBP1) for evaluation of Renpenning syndrome


name: Level 5 molecular pathology procedure - Deletion and duplication analysis of proteolipid protein 1 (PLP1) for evaluation of Pelizaeus-Merzbacher disease


name: Level 5 molecular pathology procedure - Deletion and duplication analysis of proteolipid protein 1 (PLP1) for evaluation of spastic paraplegia


name: Level 5 molecular pathology procedure - Deletion and duplication analysis of sarcoglycan, gamma (35kDa dystrophin-associated glycoprotein) (SGCG) for the evaluation of limb-girdle muscular dystrophy


name: Level 5 molecular pathology procedure - Deletion and duplication analysis of serine/threonine kinase 11 (STK11) for the evaluation of Peutz-Jeghers syndrome


name: Level 5 molecular pathology procedure - Deletion and duplication analysis of solute carrier family 16, member 2 (thyroid hormone transporter) (SLC16A2) for the evaluation of Allan-Herndon-Dudley syndrome


name: Level 5 molecular pathology procedure - Deletion and duplication analysis of solute carrier family 16, member 2 (thyroid hormone transporter) (SLC16A2) for the evaluation of specific thyroid hormone cell transporter deficiency


name: Level 5 molecular pathology procedure - Deletion and duplication analysis of solute carrier family 25 (carnitine/acylcarnitine translocase), member 20 (SLC25A20) for evaluation of carnitine-acylcarnitine translocase deficiency


name: Level 5 molecular pathology procedure - Deletion and duplication analysis of succinate dehydrogenase complex, subunit C, integral membrane protein, 15kDa (SDHC) for the evaluation of hereditary paraganglioma-pheochromocytoma syndrome


name: Level 5 molecular pathology procedure - Deletion and duplication analysis of zinc finger E-box binding homeobox 2 (ZEB2) for evaluation of Mowat-Wilson syndrome


name: Level 5 molecular pathology procedure - Duplication analysis of HNF1 homeobox B (HBB) for evaluation of maturity-onset diabetes of the young (MODY)


name: Level 5 molecular pathology procedure - Duplication analysis of MpV17 mitochondrial inner membrane protein (MPV17) for evaluation of mitochondrial DNA depletion syndrome


name: Level 5 molecular pathology procedure - Duplication analysis of emerin (EMD) for evaluation of Emery-Dreifuss muscular dystrophy


name: Level 5 molecular pathology procedure - Duplication analysis of multiple endocrine neoplasia I (MEN1) for evaluation of Werner syndrome


name: Level 5 molecular pathology procedure - Duplication analysis of multiple endocrine neoplasia I (MEN1) for evaluation of multiple endocrine neoplasia type 1


name: Level 5 molecular pathology procedure - Duplication analysis of neuroligin 4, X-linked (NLGN4X) for the evaluation of autism spectrum disorders


name: Level 5 molecular pathology procedure - Duplication analysis of polyglutamine binding protein 1 (PQBP1) for evaluation of Renpenning syndrome


name: Level 5 molecular pathology procedure - Duplication analysis of proteolipid protein 1 (PLP1) for evaluation of Pelizaeus-Merzbacher disease


name: Level 5 molecular pathology procedure - Duplication analysis of proteolipid protein 1 (PLP1) for evaluation of spastic paraplegia


name: Level 5 molecular pathology procedure - Duplication analysis of sarcoglycan, gamma (35kDa dystrophin-associated glycoprotein) (SGCG) for the evaluation of limb-girdle muscular dystrophy


name: Level 5 molecular pathology procedure - Duplication analysis of serine/threonine kinase 11 (STK11) for the evaluation of Peutz-Jeghers syndrome


name: Level 5 molecular pathology procedure - Duplication analysis of solute carrier family 16, member 2 (thyroid hormone transporter) (SLC16A2) for the evaluation of Allan-Herndon-Dudley syndrome


name: Level 5 molecular pathology procedure - Duplication analysis of solute carrier family 16, member 2 (thyroid hormone transporter) (SLC16A2) for the evaluation of specific thyroid hormone cell transporter deficiency


name: Level 5 molecular pathology procedure - Duplication analysis of solute carrier family 25 (carnitine/acylcarnitine translocase), member 20 (SLC25A20) for evaluation of carnitine-acylcarnitine translocase deficiency


name: Level 5 molecular pathology procedure - Duplication analysis of succinate dehydrogenase complex, subunit C, integral membrane protein, 15kDa (SDHC) for the evaluation of hereditary paraganglioma-pheochromocytoma syndrome


name: Level 5 molecular pathology procedure - Duplication analysis of zinc finger E-box binding homeobox 2 (ZEB2) for evaluation of Mowat-Wilson syndrome


name: Level 5 molecular pathology procedure - Fibroblast growth factor 23 (FGF23) full gene sequence analysis


name: Level 5 molecular pathology procedure - Full gene sequence analysis arginine vasopressin receptor 2 (AVPR2) for evaluation of nephrogenic diabetes insipidus


name: Level 5 molecular pathology procedure - Full gene sequence analysis of - Bardet-Biedl syndrome 10 (BBS10) for evaluation of Bardet-Biedl syndrome


name: Level 5 molecular pathology procedure - Full gene sequence analysis of CD40 ligand (CD40LG) for evaluation of X-linked hyper IgM syndrome


name: Level 5 molecular pathology procedure - Full gene sequence analysis of Carnitine palmitoyltransferase 2 (CPT2) for evaluation of carnitine palmitoyltransferase II deficiency


name: Level 5 molecular pathology procedure - Full gene sequence analysis of Caveolin 3 (CAV3) for evaluation of CAV-3-related distal myopathy


name: Level 5 molecular pathology procedure - Full gene sequence analysis of Caveolin 3 (CAV3) for evaluation of limb-girdle muscular dystrophy type 1C


name: Level 5 molecular pathology procedure - Full gene sequence analysis of Chromosome 10 open reading frame 2 (C10orf2) for evaluation of mitochondrial DNA depletion syndrome


name: Level 5 molecular pathology procedure - Full gene sequence analysis of Clarin 1 (CLRN1) for evaluation of Usher syndrome, type 3


name: Level 5 molecular pathology procedure - Full gene sequence analysis of Fukutin related protein (FKRP) for evaluation of congenital muscular dystrophy type 1C (MDC1C)


name: Level 5 molecular pathology procedure - Full gene sequence analysis of Fukutin related protein (FKRP) for evaluation of limb-girdle muscular dystrophy (LGMD) type 2l


name: Level 5 molecular pathology procedure - Full gene sequence analysis of Insulin (INS) for evaluation of diabetes mellitus


name: Level 5 molecular pathology procedure - Full gene sequence analysis of Lipopolysaccharide-induced TNF factor (LITAF) for evaluation of Charcot-Marie-Tooth


name: Level 5 molecular pathology procedure - Full gene sequence analysis of Mediterranean fever (MEFV) for evaluation of familial Mediterranean fever


name: Level 5 molecular pathology procedure - Full gene sequence analysis of NADH dehydrogenase [ubiquinone] 1 alpha subcomplex, 1, 7.5kDa (NDUFA1) for evaluation of Leigh syndrome


name: Level 5 molecular pathology procedure - Full gene sequence analysis of NADH dehydrogenase [ubiquinone] 1 alpha subcomplex, 1, 7.5kDa (NDUFA1) for evaluation of mitochondrial complex I deficiency


name: Level 5 molecular pathology procedure - Full gene sequence analysis of NADH dehydrogenase [ubiquinone] 1 alpha subcomplex, assembly factor 2 (NDUFAF2) for evaluation of Leigh syndrome


name: Level 5 molecular pathology procedure - Full gene sequence analysis of NADH dehydrogenase [ubiquinone] 1 alpha subcomplex, assembly factor 2 (NDUFAF2) for evaluation of mitochondrial complex I deficiency


name: Level 5 molecular pathology procedure - Full gene sequence analysis of NADH dehydrogenase [ubiquinone] Fe-S protein 4, 18kDa [NADH-coenzyme Q reductase] (NDUFS4) for evaluation of Leigh syndrome


name: Level 5 molecular pathology procedure - Full gene sequence analysis of NADH dehydrogenase [ubiquinone] Fe-S protein 4, 18kDa [NADH-coenzyme Q reductase] (NDUFS4) for evaluation of mitochondrial complex I deficiency


name: Level 5 molecular pathology procedure - Full gene sequence analysis of Niemann-Pick disease, type C2 (epididymal secretory protein E1) (NPC2) for evaluation of Niemann-Pick disease, type C2


name: Level 5 molecular pathology procedure - Full gene sequence analysis of Norrie disease (pseudoglioma) (NDP) for evaluation of Norrie disease


name: Level 5 molecular pathology procedure - Full gene sequence analysis of PROP paired-like homeobox 1 (PROP1) for evaluation of combined pituitary hormone deficiency


name: Level 5 molecular pathology procedure - Full gene sequence analysis of SCO cytochrome oxidase deficient homolog 2 (SCO1L) (SCO2) for the evaluation of mitochondrial respiratory chain complex IV deficiency


name: Level 5 molecular pathology procedure - Full gene sequence analysis of SH2 domain containing 1A (SH2D1A) for the evaluation of X-linked lymphoproliferative syndrome


name: Level 5 molecular pathology procedure - Full gene sequence analysis of Sodium channel, voltage-gated, type I, beta (SCN1B) for the evaluation of Brugada syndrome


name: Level 5 molecular pathology procedure - Full gene sequence analysis of THAP domain containing, apoptosis associated protein 1 (THAP1) for the evaluation of torsion dystonia


name: Level 5 molecular pathology procedure - Full gene sequence analysis of Usher syndrome 1G (autosomal recessive) (USH1G) for evaluation of Usher syndrome type 1


name: Level 5 molecular pathology procedure - Full gene sequence analysis of V-Ha-ras Harvey rat sarcoma viral oncogene homolog (HRAS) for evaluation of von Hippel-Lindau familial cancer syndrome


name: Level 5 molecular pathology procedure - Full gene sequence analysis of aquaporin 2 [collecting duct] (AQP2) for evaluation of nephrogenic diabetes insipidus


name: Level 5 molecular pathology procedure - Full gene sequence analysis of biotinidase (BTD) for evaluation of biotinidase deficiency


name: Level 5 molecular pathology procedure - Full gene sequence analysis of cone-rod homeobox (CRX) for evaluation of Leber congenital amaurosis


name: Level 5 molecular pathology procedure - Full gene sequence analysis of cone-rod homeobox (CRX) for evaluation of cone-rod dystrophy 2


name: Level 5 molecular pathology procedure - Full gene sequence analysis of cyclin-dependent kinase inhibitor 2A (CDKN2A) for evaluation of CDKN2A-related cutaneous malignant melanoma


name: Level 5 molecular pathology procedure - Full gene sequence analysis of cyclin-dependent kinase inhibitor 2A (CDKN2A) for evaluation of familial atypical mole-malignant melanoma syndrome


name: Level 5 molecular pathology procedure - Full gene sequence analysis of cytochrome c oxidase subunit VIb polypeptide 1 (COX6B1) for evaluation of mitochondrial respiratory chain complex IV deficiency


name: Level 5 molecular pathology procedure - Full gene sequence analysis of early growth response 2 (EGR2) for evaluation of Charcot-Marie-Tooth


name: Level 5 molecular pathology procedure - Full gene sequence analysis of eat shock 27kDa protein 1 (HSPB1) for evaluation of Charcot-Marie-Tooth disease


name: Level 5 molecular pathology procedure - Full gene sequence analysis of epilepsy, progressive myoclonus type 2A, Lafora disease (laforin) (EPM2A) for evaluation of progressive myoclonus epilepsy


name: Level 5 molecular pathology procedure - Full gene sequence analysis of fibroblast growth factor 23 (FGF23) for evaluation of hypophosphatemic rickets


name: Level 5 molecular pathology procedure - Full gene sequence analysis of forkhead box G1 (FOXG1) for evaluation of Rett syndrome


name: Level 5 molecular pathology procedure - Full gene sequence analysis of four and a half LIM domains 1 (FHL1) for evaluation of Emery-Dreifuss muscular dystrophy


name: Level 5 molecular pathology procedure - Full gene sequence analysis of glycoprotein Ib [platelet], beta polypeptide (GP1BB) for evaluation of Bernard-Soulier syndrome type B


name: Level 5 molecular pathology procedure - Full gene sequence analysis of growth hormone 1 (GH1) for evaluation of growth hormone deficiency


name: Level 5 molecular pathology procedure - Full gene sequence analysis of hydroxysteroid [11-beta] dehydrogenase 2 (HSD11B2) for evaluation of mineralocorticoid excess syndrome


name: Level 5 molecular pathology procedure - Full gene sequence analysis of methylmalonic aciduria [cobalamin deficiency] cblC type, with homocystinuria (MMACHC) for evaluation of acidemia and homocystinuria


name: Level 5 molecular pathology procedure - Full gene sequence analysis of non-imprinted in Prader-Willi/Angelman syndrome 1 (NIPA1) for evaluation of spastic paraplegia


name: Level 5 molecular pathology procedure - Full gene sequence analysis of nuclear receptor subfamily 0, group B, member 1 (NR0B1) for evaluation of congenital adrenal hypoplasia


name: Level 5 molecular pathology procedure - Full gene sequence analysis of paired-like homeobox 2b (PHOX2B) for evaluation of congenital central hypoventilation syndrome


name: Level 5 molecular pathology procedure - Full gene sequence analysis of pancreatic and duodenal homeobox 1 (PDX1) for evaluation of maturity-onset diabetes of the young (MODY)


name: Level 5 molecular pathology procedure - Full gene sequence analysis of peripherin 2 [retinal degeneration, slow] (PRPH2) for evaluation of retinitis pigmentosa


name: Level 5 molecular pathology procedure - Full gene sequence analysis of potassium inwardly-rectifying channel, subfamily J, member 1 (KCNJ1) for evaluation of Bartter syndrome


name: Level 5 molecular pathology procedure - Full gene sequence analysis of potassium inwardly-rectifying channel, subfamily J, member 10 (KCNJ10) for evaluation of EAST syndrome


name: Level 5 molecular pathology procedure - Full gene sequence analysis of potassium inwardly-rectifying channel, subfamily J, member 10 (KCNJ10) for evaluation of SeSAME syndrome


name: Level 5 molecular pathology procedure - Full gene sequence analysis of potassium inwardly-rectifying channel, subfamily J, member 10 (KCNJ10) for evaluation of sensorineural hearing loss


name: Level 5 molecular pathology procedure - Full gene sequence analysis of prion protein (PRNP) for evaluation of genetic prion disease


name: Level 5 molecular pathology procedure - Full gene sequence analysis of protease, serine, 1 (trypsin 1) (PRSS1) for evaluation of hereditary pancreatitis


name: Level 5 molecular pathology procedure - Full gene sequence analysis of retinitis pigmentosa 1 (RP1) for the evaluation of retinitis pigmentosa


name: Level 5 molecular pathology procedure - Full gene sequence analysis of rhodopsin (RHO) for the evaluation of retinitis pigmentosa


name: Level 5 molecular pathology procedure - Full gene sequence analysis of serine peptidase inhibitor, Kazal type 1 (SPINK1) for the evaluation of hereditary pancreatitis


name: Level 5 molecular pathology procedure - Full gene sequence analysis of solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 4 (SLC25A4) for the evaluation of progressive external ophthalmoplegia


name: Level 5 molecular pathology procedure - Full gene sequence analysis of succinate dehydrogenase complex, subunit D, integral membrane protein (SDHD) for the evaluation of hereditary paraganglioma


name: Level 5 molecular pathology procedure - Full gene sequence analysis of superoxide dismutase 1, soluble (SOD1) for the evaluation of amyotrophic lateral sclerosis


name: Level 5 molecular pathology procedure - Full gene sequence analysis of tocopherol [alpha] transfer protein (TTPA) for evaluation of ataxia


name: Level 5 molecular pathology procedure - Full gene sequence analysis of torsin family 1, member A [torsin A] (TOR1A) for evaluation of torsion dystonia


name: Level 5 molecular pathology procedure - Full gene sequence analysis of translational activator of mitochondrial encoded cytochrome c oxidase I (TACO1) for the evaluation of mitochondrial respiratory chain complex IV deficiency